As per a recent study released by Maximize Market Research, titled, “Precision Oncology Market,” The Precision Oncology Market, is worth USD 98.36 billion in 2023 and is estimated to grow at a CAGR of 9.9% in the forecasted period. The forecasted revenue hints at a growth of around 190.46 billion USD by 2030.
Precision Oncology Market Overview:
Precision oncology refers to a cancer-care approach that uses detailed molecular and genetic information about a patient’s tumour (and sometimes their germline genetics) to personalise therapy. Instead of “one-size-fits-all” chemotherapy or radiotherapy, precision oncology aims to match specific molecular alterations (gene mutations, amplifications, fusions, biomarker signatures) with targeted therapies or diagnostics so that treatment is more effective and side-effects are minimised.
In parallel with therapeutics, precision oncology encompasses diagnostics (such as next-generation sequencing, biomarker panels, liquid biopsies), as well as data-analytics, bioinformatics, treatment-decision support and adaptive clinical trial designs. As our biological understanding of cancer grows, and technologies for molecular profiling become more accessible and efficient, the precision oncology model is increasingly influencing how oncology care is delivered.
Want to Preview the Full Report? Download Your Free Sample Now :https://www.maximizemarketresearch.com/request-sample/188401/
Precision Oncology Market Dynamics
One of the key growth drivers for the precision oncology market is the escalating global cancer burden coupled with the rising need for more effective treatment options. With cancer incidence increasing and survival gains stagnating in many tumour types, healthcare systems and providers are turning toward precision strategies to improve outcomes and reduce costs.
Another major driver is the accelerating technology ecosystem: falling costs of genomic sequencing, advances in biomarker discovery, improvements in bioinformatics and the integration of AI in treatment decision support frameworks. These innovations lower barriers to adoption of precision oncology solutions.
Precision Oncology Market Outlook and Future Trends :
Looking ahead, the precision oncology market is poised for robust expansion, both in terms of adoption and value. One trend to watch is the growth not just of targeted-therapies matched to biomarkers, but of combination therapies (targeted + immunotherapy), multimodal diagnostics (genomics + liquid biopsy + imaging) and adaptive treatment strategies that evolve with the tumour’s biology.
Another important trend is digital and data-driven oncology: the use of AI/machine learning for treatment-selection, prediction of response or resistance, real-time monitoring of tumour evolution and integration of multi-omics data for individualized care. As these capabilities mature, precision oncology will become more systematic, less experimental, and more integrated into mainstream oncology practice.
Precision Oncology Market Regional Insights:
Regionally, North America is currently the dominant market for precision oncology — driven by strong healthcare infrastructure, high R&D investment, advanced diagnostics capabilities, large pharma/biotech presence and favourable reimbursement/regulatory frameworks.
In contrast, the Asia-Pacific region is among the fastest-growing zones. Increased cancer incidence, expanding diagnostics infrastructures, rising healthcare spending, and growing adoption of precision oncology in countries like China, India, Japan support rapid uptake. Challenges such as cost, logistical infrastructure and regulatory variance remain, but growth potential is strong.
Precision Oncology Market Segmentation
by Products
Diagnostics
Therapeutics
by Cancer Types
Breast Cancer
Lung Cancer
Cervical cancer
Colorectal Cancer
Prostate Cancer
by End User
Pharmaceutical & Biotechnology Companies
Diagnostic Centres
Healthcare Data Companies
Some of the current players in the Precision Oncology Market are:
1. Illumina, Inc. (United States)
2. Thermo Fisher Scientific, Inc. (United States)
3. Agilent Technologies, Inc. (United States)
4. Invitae Corporation (United States)
5. NeoGenomics Laboratories, Inc. (United States)
6. Bristol Myers Squibb Company (United States)
7. Pfizer Inc. (United States)
8. Amgen Inc. (United States)
9. Merck & Co., Inc. (United States)
10. Eli Lilly and Company (United States)
11. Genomic Health, Inc. (United States)
12. Foundation Medicine, Inc. (United States)
13. Guardant Health, Inc. (United States)
14. Myriad Genetics, Inc. (United States)
15. Exact Sciences Corporation (United States)
About Maximize Market Research:
Maximize Market Research is one of the fastest-growing market research and business consulting firms serving clients globally. Our revenue impact and focused growth-driven research initiatives make us a proud partner of majority of the Fortune 500 companies. We have a diversified portfolio and serve a variety of industries such as IT & telecom, chemical, food & beverage, aerospace & defense, healthcare and others.
Contact Maximize Market Research:
MAXIMIZE MARKET RESEARCH PVT. LTD.
⮝ 3rd Floor, Navale IT park Phase 2,
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India.
✆ +91 9607365656
🖂 [email protected]
